ANI PHARMACEUTICALS, INC Excess Tax Benefit from Share-based Compensation, Financing Activities
ANI PHARMACEUTICALS, INC (ANIP) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-02-27
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $0.00.
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $617.00K, a 71.39% increase from fiscal 2015.
- ANI PHARMACEUTICALS, INC excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $360.00K, a 54.08% decline from fiscal 2014.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-27 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $0.00 derived: sum of 3 quarters · filed 2019-02-27 | $0.00 10-K · filed 2019-02-27 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 derived: sum of 2 quarters · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | $310.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | $310.00K derived: sum of 3 quarters · filed 2019-02-27 | $598.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 | $310.00K derived: sum of 2 quarters · filed 2019-02-27 | $598.00K derived: sum of 3 quarters · filed 2019-02-27 | $616.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $598.00K derived: sum of 2 quarters · filed 2019-02-27 | $616.00K derived: sum of 3 quarters · filed 2019-02-27 | $617.00K 10-K · filed 2019-02-27 |
| 2016-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $306.00K derived: sum of 2 quarters · filed 2017-11-02 | $307.00K 10-Q · filed 2017-11-02 | $433.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $19.00K 10-Q · filed 2017-08-03 | $145.00K derived: sum of 3 quarters · filed 2018-02-27 | $332.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $1.00K 10-Q · filed 2017-05-04 | $127.00K derived: sum of 2 quarters · filed 2018-02-27 | $314.00K derived: sum of 3 quarters · filed 2018-02-27 | $352.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $313.00K derived: sum of 2 quarters · filed 2018-02-27 | $351.00K derived: sum of 3 quarters · filed 2018-02-27 | $360.00K 10-K · filed 2018-02-27 |
| 2015-09-30 | $187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $225.00K derived: sum of 2 quarters · filed 2016-11-03 | $234.00K 10-Q · filed 2016-11-03 | $586.00K derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $47.00K 10-Q · filed 2016-08-04 | $399.00K derived: sum of 3 quarters · filed 2017-03-02 | $823.00K derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-03-31 | $9.00K 10-Q · filed 2016-05-05 | $361.00K derived: sum of 2 quarters · filed 2017-03-02 | $785.00K derived: sum of 3 quarters · filed 2017-03-02 | $686.00K derived: sum of 4 quarters · filed 2017-03-02 |
| 2014-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $776.00K derived: sum of 2 quarters · filed 2017-03-02 | $677.00K derived: sum of 3 quarters · filed 2017-03-02 | $784.00K 10-K · filed 2017-03-02 |
| 2014-09-30 | $424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $325.00K derived: sum of 2 quarters · filed 2015-11-03 | $432.00K 10-Q · filed 2015-11-03 | $432.00K derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-06-30 | -$99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $8.00K 10-Q · filed 2015-08-04 | $8.00K derived: sum of 3 quarters · filed 2016-02-23 | $8.00K derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-03-31 | $107.00K 10-Q · filed 2015-05-05 | $107.00K derived: sum of 2 quarters · filed 2016-02-23 | $107.00K derived: sum of 3 quarters · filed 2016-02-23 | $107.00K derived: sum of 4 quarters · filed 2016-02-23 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $0.00 derived: sum of 2 quarters · filed 2016-02-23 | $0.00 derived: sum of 3 quarters · filed 2016-02-23 | $0.00 10-K · filed 2016-02-23 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $0.00 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |